Magazine article Drug Topics

Amneal Pharmaceuticals Focuses on the Business by Serving Customers

Magazine article Drug Topics

Amneal Pharmaceuticals Focuses on the Business by Serving Customers

Article excerpt

Amneal Pharmaceuticals is a generic drug company on the move. It has climbed to No. 8 in the generic drug market for prescriptions dispensed, according to IMS Health 2010. Product diversification, acquisition of a new manufacturing plant, and research and development (R&D) expansion are forging ahead.

Nearly 70 approved medications are now on the market. The firm plans to launch several new products by the close of 2011 and more in the next 3 years. Earlier this year, Amneal introduced the first generic Nitrofurantoin Suspension, lndomethacin Extended Release Capsules, Risperidone Solution and Venlafaxine Tablets, to name just a few. Since January, the company has introduced 8 families of solid products and 6 families of liquid products.

Amneal's product pipeline is entering new therapeutic areas and expanding its controlled-substance product line. A substantial increase in the number of soft gels is expected. A variety of new dosage forms are also in the pipeline. Injectables, transdermal patches, nasal sprays, creams, and ointments will enhance product growth for the firm.

Amneal's acquisition of an additional production plant and investment in higher-volume manufacturing equipment have enabled it to grow rapidly. One indicator of its phenomenal growth spurt is the quadrupling of its tablet volume alone - from 320 million tablets in September 2009 to 1.3 billion tablets as of June 2011.

Amneal is excelling in just about every part of its operations, and expansion of R&D is particularly impressive. Strong R&D capability can be seen in the growth of its dedicated lab space in multiple locations, including Brookhaven, N. Y., Branchburg, N.J., and Piscataway, NJ. as well as the company's R&D Centre in Ahmedabad, Gujarat, India.

Sales, operations, and distribution have also shown striking growth. Amneal's new facility in Glasgow, KY, boasts 115,000 square feet for distribution and sales operations. With the opening of the facility in September 2010, the company's capacity dramatically increased.

The site was specifically selected due to its expansion capabilities as the company grows.

The Glasgow facility also offers complete EDI interaction, such as case- level bar-code tracking for all orders and products, which are e-Pedigree ready to the unit level. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed


An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.